Showing results (1751-1760 of 1,803) with videos related to
Sort By:
Pageof 181
IEEE Journal of Translational Engineering in Health and Medicine|October 13, 2016
National Institute of Biomedical Imaging and Bioengineering Point-of-Care Technology Research Network: Advancing Precision MedicinePenny Ford Carleton, Steven Schachter, John A Parrish, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2013
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanomaAntoni Ribas, Richard Kefford, Margaret A Marshall, et al.Molecular Genetics and Metabolism|October 31, 2023
Variant Classification for Pompe disease; ACMG/AMP specifications from the ClinGen Lysosomal Diseases Variant Curation Expert PanelJennifer L Goldstein, Jennifer McGlaughon, Dona Kanavy, et al.The Lancet. Oncology|October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialJean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.The New England Journal of Medicine|November 18, 2014
Improved overall survival in melanoma with combined dabrafenib and trametinibCaroline Robert, Boguslawa Karaszewska, Jacob Schachter, et al.European Journal of Cancer (Oxford, England : 1990)|December 28, 2020
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanomaCaroline Robert, Wen-Jen Hwu, Omid Hamid, et al.Neurology|July 23, 1998
Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trialA Handforth, C M DeGiorgio, S C Schachter, et al.Epilepsy & Behavior : E&B|June 15, 2013
Epilepsy, behavior, and art (Epilepsy, Brain, and Mind, part 1)Ivan Rektor, Steven C Schachter, Shahar Arzy, et al.European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsDirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.Epilepsia|April 23, 2004
Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy SocietyJacqueline A French, Andres M Kanner, Jocelyn Bautista, et al.Pageof 181